Ovid Therapeutics (OVID) Earnings Date, Estimates & Call Transcripts $0.84 -0.02 (-2.06%) Closing price 04:00 PM EasternExtended Trading$0.83 -0.01 (-0.75%) As of 06:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Ovid Therapeutics Earnings Summary Ovid Therapeutics posted Q2 2025 earnings on August 13, 2025, reporting an EPS of -$0.06, which beat the consensus estimate of -$0.16 by $0.10. Quarterly revenue was reported to be $6.27 million, above the consensus estimate of $0.09 million. With a trailing EPS of -$0.35, Ovid Therapeutics' earnings are expected to decrease next year, from ($0.40) to ($0.64) per share. Latest Q2 Earnings DateAug. 13EstimatedConsensus EPS (Aug. 13) -$0.16 Actual EPS (Aug. 13) -$0.06 Beat By $0.10 Actual Revenue (Aug. 13) $6.27MQ2 2025 Earnings ResourcesQ2 2025 Earnings Report Quarterly Report (10-Q) Press Release (8-K)Powered by Get Ovid Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ovid Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataOVID Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.OVID Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ovid Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20253-$0.13-$0.13-$0.13Q2 20254-$0.16-$0.14-$0.15Q3 20254-$0.16-$0.12-$0.14Q4 20254-$0.17-$0.12-$0.14 FY 2025 15 -$0.62 -$0.51 -$0.57 Q1 20263-$0.17-$0.11-$0.14Q2 20263-$0.17-$0.09-$0.14Q3 20263-$0.19-$0.10-$0.14Q4 20263-$0.21-$0.11-$0.16 Ovid Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025-$0.16-$0.06+$0.10-$0.06$0.09M$6.27M5/13/2025Q1 2025-$0.14-$0.14--$0.14$0.03M$0.13M3/11/2025Q4 2024-$0.16-$0.13+$0.03-$0.13$0.19M$0.08M11/12/2024--$0.19-$0.20 -$0.01-$0.20$0.15M$0.17M8/13/2024Q2 2024-$0.22$0.12+$0.34$0.12$0.14M$0.17M5/14/2024Q1 2024-$0.23-$0.17+$0.06-$0.17$0.11M$0.15M3/8/2024Q4 2023-$0.17-$0.22 -$0.05-$0.22$0.10M$0.14M11/3/2023Q3 2023-$0.18-$0.16+$0.02-$0.16$0.09M$0.11M Ovid Therapeutics Earnings - Frequently Asked Questions When did Ovid Therapeutics announce their last quarterly earnings? Ovid Therapeutics (NASDAQ:OVID) last announced its quarterly earning data on Wednesday, August 13, 2025. Learn more on OVID's earnings history. Did Ovid Therapeutics beat their earnings estimates last quarter? In the previous quarter, Ovid Therapeutics (NASDAQ:OVID) reported ($0.06) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.16) by $0.10. Learn more on analysts' earnings estimate vs. OVID's actual earnings. How much revenue does Ovid Therapeutics generate each year? Ovid Therapeutics (NASDAQ:OVID) has a recorded annual revenue of $570,000.00. How much profit does Ovid Therapeutics generate each year? Ovid Therapeutics (NASDAQ:OVID) has a recorded net income of -$26.43 million. OVID has generated -$0.35 earnings per share over the last four quarters. What is Ovid Therapeutics' EPS forecast for next year? Ovid Therapeutics' earnings are expected to decrease from ($0.40) per share to ($0.64) per share in the next year. More Earnings Resources from MarketBeat Related Companies NVCT Earnings Results GNLX Earnings Results CGEN Earnings Results KRRO Earnings Results SPRO Earnings Results BHST Earnings Results FATE Earnings Results MCRB Earnings Results IMRX Earnings Results PLX Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Brinker Serves Up Earnings Beat, Sidesteps Cost PressuresWhy BigBear.ai Stock's Dip on Earnings Can Be an Opportunity CrowdStrike Faces Valuation Test Before Key Earnings ReportPost-Earnings, How Does D-Wave Stack Up Against Quantum Rivals?Why SoundHound AI's Earnings Show the Stock Can Move HigherAirbnb Beats Earnings, But the Growth Story Is Losing AltitudeDutch Bros Just Flipped the Script With a Massive Earnings Beat This page (NASDAQ:OVID) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ovid Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Ovid Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access